ASH Data Raise Hopes For Ibrutinib As Single Agent, Chemo-Free Option In CLL
This article was originally published in The Pink Sheet Daily
Executive Summary
With the latest response, safety and durability data creating a buzz at the American Society of Hematology, Pharmacyclics CMO Lori Anne Kunkel discusses possibility for accelerated approval in a high-risk type of chronic lymphocytic leukemia. Drug also shows promise in trials of a genetic subtype of diffuse large B-cell lymphoma and mantle cell lymphoma.